List view / Grid view
5 February 2016 | By Victoria White
The Phase 3 GAUSS-3 trial evaluating Amgen’s Repatha (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints...
5 February 2016 | By Victoria White
NovaBiotics was awarded the Life Science Investment of the Year Award at the Scottish Enterprise Life Sciences Annual Awards...
Flame-NIR puts the power of NIR analysis in a small-footprint instrument...
5 February 2016 | By Victoria White
Blincyto is a BiTE antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells...
5 February 2016 | By Victoria White
Overall, the review demonstrates that US pharma industry and domestic manufacturers are showing increased confidence of renewed growth...
4 February 2016 | By L.B. Bohle Maschinen + Verfahren GmbH
Continuous processing for secondary manufacturing in pharma is still one of the hottest topics currently discussed...
4 February 2016 | By Victoria White
AST-OPC1 has three potentially reparative functions that address the complex pathologies observed at the injury site of a spinal cord injury...
4 February 2016 | By Victoria White
The FDA Advisory Committee reviewed data from studies designed to assess the effect of Brintellix on cognitive dysfunction in adult patients with MDD...
4 February 2016 | By Victoria White
Unlike other asthma daily maintenance treatments, Spiriva Respimat is from a new class of medications in asthma known as long-acting anticholinergics...
To overcome the need of method developers for faster and high-resolution methods, YMC now offers all of its CHIRAL ART polysaccharide HPLC columns with a particle size of 3 µm.
3 February 2016 | By Victoria White
The FDA has granted the designation for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer...
3 February 2016 | By Victoria White
Proton Partners International have received formal planning permission to build the proton beam therapy clinic in Northumberland...
3 February 2016 | By Victoria White
GlobalData says the treatment market for head and neck cancer will expand almost fourfold from $386 million in 2014 to $1.53 billion...
3 February 2016 | By Victoria White
Celyad has appointed Dr Richard Mountfield as Vice-President of Global Regulatory Affairs...
3 February 2016 | By Victoria White
The submission seeks an expanded indication for Flulaval Quadrivalent in the US for children six months through 35 months of age...
